Imati et al. demonstrated that the anti-osteoclastic effect of the HDAC6 inhibitor panobinostat was related with the degradation of PPP3CA, a catalytic subunit of calcineurin, in MM cell lines [10]. Here, HDAC6 is linked to Miyoshi myopathy.